Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ReViral names Pharmasset founder as board member

This article was originally published in Scrip

Executive Summary

Cardiff, UK-based ReViral, an antiviral drug discovery and development company focused on diseases caused by the respiratory syncytial virus (RSV), has named Professor Raymond Schinazi to its board as a non-executive director – effective from 9 April 2014. Professor Schinazi is the founder of several biotechnology companies including Pharmasset (acquired by Gilead, January 2012), where he chaired the company's board during the discovery of hepatitis C drug Sovaldi (sofosbuvir).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel